Amir Hossein Aalami1, Hossein Abdeahad2, Mohammad Mesgari3. 1. Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran. 2. Department of Nutrition and Integrative Physiology, Collogue of Health, University of Utah, Salt Lake City, UT, 84112, USA. 3. Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran.
Abstract
PURPOSE: Gastrointestinal cancers (GICs) account for about a quarter of cancers. Lately, the circulating microRNAs as a non-invasive biomarker for identifying and monitoring diseases have been recognized. Several studies have examined the role of miR-21 in digestive system carcinoma. We conducted a meta-analysis to assess the diagnostic role of miR-21 in GICs. Methods Seventeen studies involving 1700 individuals were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, DOR, AUC, SROC, and Q* index were calculated based on true-positive, true-negative, false-negative, and false-positive. Moreover, the subgroup analyses have been performed for miR-21 based on sample types (serum/plasma), normalized genes (U6, miR-16, and miR-39), and ethnicity. RESULTS: The pooled sensitivity 0.722 (95% CI: 0.70 - 0.74), specificity 0.820 (95% CI: 0.801 - 0.838), PLR 4.375 (95% CI: 3.226 - 5.933), NLR 0.308 (95% CI: 0.239 - 0.398), DOR 16.06 (95% CI: 9.732 - 26.53) as well as AUC 0.86, and Q* index 0.79 represented the high-grade diagnostic precision of miR-21 in identifying GICs (ESCC, GC, CRC, HCC, and PC). CONCLUSION: This meta-analysis demonstrated that circulating miR-21 levels can be used to monitor the digestive system carcinomas. Therefore, miR-21 can be a useful biomarker of progression and fair diagnosis in GICs patients.
PURPOSE:Gastrointestinal cancers (GICs) account for about a quarter of cancers. Lately, the circulating microRNAs as a non-invasive biomarker for identifying and monitoring diseases have been recognized. Several studies have examined the role of miR-21 in digestive system carcinoma. We conducted a meta-analysis to assess the diagnostic role of miR-21 in GICs. Methods Seventeen studies involving 1700 individuals were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, DOR, AUC, SROC, and Q* index were calculated based on true-positive, true-negative, false-negative, and false-positive. Moreover, the subgroup analyses have been performed for miR-21 based on sample types (serum/plasma), normalized genes (U6, miR-16, and miR-39), and ethnicity. RESULTS: The pooled sensitivity 0.722 (95% CI: 0.70 - 0.74), specificity 0.820 (95% CI: 0.801 - 0.838), PLR 4.375 (95% CI: 3.226 - 5.933), NLR 0.308 (95% CI: 0.239 - 0.398), DOR 16.06 (95% CI: 9.732 - 26.53) as well as AUC 0.86, and Q* index 0.79 represented the high-grade diagnostic precision of miR-21 in identifying GICs (ESCC, GC, CRC, HCC, and PC). CONCLUSION: This meta-analysis demonstrated that circulating miR-21 levels can be used to monitor the digestive system carcinomas. Therefore, miR-21 can be a useful biomarker of progression and fair diagnosis in GICs patients.